These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 25919841)

  • 1. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
    Zhou X; Ravindran AV; Qin B; Del Giovane C; Li Q; Bauer M; Liu Y; Fang Y; da Silva T; Zhang Y; Fang L; Wang X; Xie P
    J Clin Psychiatry; 2015 Apr; 76(4):e487-98. PubMed ID: 25919841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
    Yan Y; Yang X; Wang M; Chen B; Yin L; Ma X
    Psychol Med; 2022 Sep; 52(12):2224-2231. PubMed ID: 35993319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.
    Maneeton N; Maneeton B; Srisurapanont M; Martin SD
    BMC Psychiatry; 2012 Sep; 12():160. PubMed ID: 23017200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
    Nuñez NA; Joseph B; Pahwa M; Kumar R; Resendez MG; Prokop LJ; Veldic M; Seshadri A; Biernacka JM; Frye MA; Wang Z; Singh B
    J Affect Disord; 2022 Apr; 302():385-400. PubMed ID: 34986373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.
    Chang CM; Sato S; Han C
    CNS Drugs; 2013 May; 27 Suppl 1():S21-7. PubMed ID: 23712796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
    Zhou X; Teng T; Zhang Y; Del Giovane C; Furukawa TA; Weisz JR; Li X; Cuijpers P; Coghill D; Xiang Y; Hetrick SE; Leucht S; Qin M; Barth J; Ravindran AV; Yang L; Curry J; Fan L; Silva SG; Cipriani A; Xie P
    Lancet Psychiatry; 2020 Jul; 7(7):581-601. PubMed ID: 32563306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the comparative benefits and harms of augmentation treatments in major depression?
    Shelton RC
    J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
    Terao I; Tsuge T; Endo K; Kodama W
    J Affect Disord; 2024 Feb; 346():49-56. PubMed ID: 37949235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH; Bahji A; Undurraga J; Tondo L; Baldessarini RJ
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.
    Zhou X; Keitner GI; Qin B; Ravindran AV; Bauer M; Del Giovane C; Zhao J; Liu Y; Fang Y; Zhang Y; Xie P
    Int J Neuropsychopharmacol; 2015 May; 18(11):pyv060. PubMed ID: 26012350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
    Farhat LC; Behling E; Landeros-Weisenberger A; Levine JLS; Macul Ferreira de Barros P; Wang Z; Bloch MH
    Lancet Child Adolesc Health; 2023 Feb; 7(2):112-126. PubMed ID: 36528030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.